| Symbol | ABVC |
|---|---|
| Name | ABVC BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 44370 OLD WARM SPRINGS BLVD., FREMONT, California, 94538, United States |
| Telephone | +1 510 - 668-0881 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential. Additional info from NASDAQ: |
New Form DEF 14A - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-03-05 <b>AccNo:</b> 0001213900-26-024122 <b>Size:</b> 507 KB
Read moreNew Form PRE 14A - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-02-05 <b>AccNo:</b> 0001213900-26-012888 <b>Size:</b> 501 KB
Read moreNew Form 424B4 - ABVC BIOPHARMA, INC. Filed: 2025-11-14 AccNo: 0001213900-25-110900 Size: 985 KB
Read more(75% Positive) ABVC BIOPHARMA, INC. (ABVC) Announces Business Combination
Read moreNew Form 424B4 - ABVC BIOPHARMA, INC. Filed: 2025-08-15 AccNo: 0001213900-25-077489 Size: 990 KB
Read moreNew Form 424B4 - ABVC BIOPHARMA, INC. Filed: 2025-08-15 AccNo: 0001213900-25-077487 Size: 990 KB
Read moreNew Form 424B4 - ABVC BIOPHARMA, INC. Filed: 2025-08-15 AccNo: 0001213900-25-077482 Size: 990 KB
Read moreNew Form 424B4 - ABVC BIOPHARMA, INC. Filed: 2025-08-15 AccNo: 0001213900-25-077476 Size: 991 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05414747 | Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular E… | Na | Retinal Detachment | Suspended | 2023-04-15 | 2025-12-15 | ClinicalTrials.gov |
| NCT05202327 | PDC-1421 Treatment in Adult Patients With ADHD | Phase2 | Attention-Deficit Hyperactivity Disorder (ADHD) | Completed | 2022-04-07 | 2023-12-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| SF6 Gas | DEVICE | Approved | Retinal Detachment | SUSPENDED | NCT05414747 |
| ABV-1701 | DEVICE | Approved | Retinal Detachment | SUSPENDED | NCT05414747 |
| Placebo | DRUG | Phase PHASE2 | Attention-Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT05202327 |
| PDC-1421 Capsule | DRUG | Phase PHASE2 | Attention-Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT05202327 |